e-sync t cells
Cell therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 30, 2024 (NCT06186401)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Ephrin type-A receptor 2Immunity, passive
EPHA2 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06186401 | Phase 1 | Apr 30, 2024 | California Institute for Regenerative Medicine (CIRM), National Cancer Institute (NCI), University of California, San Francisco |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| California Institute for Regenerative Medicine (CIRM) | Academic/Hospital | 1 | 0 | 1 | 2024 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2024 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1